Arcus Biosciences, Inc.
RCUSHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. At a $3.08B market cap, Arcus Biosciences, Inc. ranks as a mid-cap company within healthcare. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Market Cap
$3.08B
Beta
0.87
P/E (TTM)
—
P/E (Fwd)
-7.83
EPS (TTM)
$-3.17
EPS (Fwd)
$-3.12
ROE
-70.0%
ROA
-23.1%
Cash
$822.0M
Total Debt
$113.0M
Free CF
-$156.0M
52W Change
154.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $822.0M in cash comfortably exceeding the $113.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$156.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -70.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $112.0M (2022) to $247.0M (2025), reflecting a 121% increase over the period.
With cash comfortably exceeding debt, RCUS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Arcus Biosciences, Inc. and its sector.